Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
What’s the best path for your low soluble molecule?
Two molecules, both designed to treat the same condition, both with solubility challenges. Two biopharma companies racing to be first. Biopharma A chooses to move into trials as quickly as possible, while Biopharma B decides to address broader solubility concerns first. Who gets to market first may surprise you.